肿瘤科常见分子靶向药物的临床应用分析报告.ppt

* p53蛋白抑制ras、c-myc等癌基因的转化作用，调节DNA合成的启始 很多人类的实体癌均有p53基因的突变，约70-80%的大肠癌有p53基因的突变 * CRP：C反应蛋白 * AFP具有运输大分子进入细胞、胚胎发育过程中的基因调控、生长调节等重要的生理及生化功能，介导上皮细胞之间的粘附、相互作用以及识别的功能。 甲胎蛋白(AFP):1963年前苏联Ablelev在肝癌移植小鼠中发现了AFP，次年他的同胞Tatarinov在原发性肝癌患者血中发现AFP升高。 1970年以后晚期hcc * 见于正常成年个体的肝细胞被破坏后的再生（急、慢性肝炎，重症肝炎恢复期，肝硬化）、 * - Expression of EGFR has been observed in a variety of human tumors, both in vitro and in vivo.[1-15] The increased level of expression found in many tumor types and its consequences on tumor growth provide the rationale for targeting the EGFR in cancer therapy. - The level of EGFR expression varies widely with tumor type. In certain tumor types, EGFR expression is very common. - Variation in EGFR expression observed within studies of a given tumor type could be due in part to a lack of consistency in detection methods, inherent biological differences between tumors, and/or stage of disease. - High levels of EGFR activity can occur as a result of elevated production of receptor ligands (EGF, TGF-alpha). - EGFR expression has been correlated with increased resistance to certain chemotherapeutic agents and radiotherapy. - Substantial evidence exists for increased EGFR expression in multiple tumor types. 1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Crit Rev Oncol Hematol 1995;19:183-232. 2. Messa C, Russo F, Caruso MG, Di Leo A. Acta Oncol 1988;37:285-289. 3. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Cancer 1996;78:1284-1292. 4. Uegaki K, Nio Y, Inoue Y, et al. Anticancer Res 1997;17:3841-3847. 5. Fujino S, Enokibori T, Tezuka N, et al. Eur J Cancer 1996;32A:2070-2074. 6. Fontanini G, DeLaurentiis M, Vignati S, et al. Clin Cancer Res 1998;4:241-249. 7. Yoshida K, Hosoya Y, Sumi S, et al. Oncology 1997;54:220-225. 8. Klijn JG, Berns PM, Schmitz PI, Foekens JA. Endocr Rev 1992;13:3-17. 9. Bucci B, DAgnano I, Botti C, et al. Anticancer Res 1997;17:769-774. 10. Walker RA, Dearing SJ. Breast Cancer Res Treat 1999;53:167-176. 11. Bartlett JM, Langdon SP, Simpson BJ, et a